BTIG analyst Mark Massaro maintained a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $65.00. The ...

Exact Sciences (NASDAQ:EXAS – Free Report) had its target price lifted by Scotiabank from $70.00 to $73.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a sector ...

Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are ...

Scotiabank raised the firm’s price target on Exact Sciences (EXAS) to $73 from $70 and keeps an Outperform rating on the shares. Exact’s Q4 was ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited ...

CIBC Asset Management Inc raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% in the fourth ...

Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss. Find out why I remain bullish on EXAS stock.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Two employers sued over the health law mandate that requires preventive care coverage but a testing firm CEO think other ...

Medical Specialities company Exact Sciences is taking Wall Street by surprise today, falling to $47.57 and marking a -5.8% ...

The latest quarterly earnings call from Exact Sciences has revealed a remarkable performance, solidifying its position as a ...